In Lancet Oncology this week, researchers in China report on the efficacy of gefitinib as a maintenance treatment for patients with locally advanced or metastatic non-small-cell lung cancer. The team randomly assigned 296 patients to receive either gefitinib or placebo within three to six week of chemotherapy, and found that progression-free survival was significantly longer with gefitinib compared to placebo.
This Week in Lancet Oncology
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.